The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The Lipid Treatment Assessment Project (L-TAP): A Multicenter Survey to Evaluate the Percentages of Dyslipidemic Patients Receiving Lipid-Lowering Therapy and Achieving Low-Density Lipoprotein Cholesterol Goals
Abstract
OBJECTIVE: To determine the percentage of patients in the multicenter Lipid Treatment Assessment Project receiving lipid-lowering therapy who are achieving low-density lipoprotein cholesterol (LDL-C) goals as defined by National Cholesterol Education Program (NCEP) guidelines. METHODS: Adult patients with dyslipidemia, who had been receiving the same lipid-lowering therapy for at least 3 months, were assessed at investigation sites. Lipid levels were determined once in each patient at the time of enrollment. The primary end point was the success rate, defined as the proportion of patients who achieved their LDL-C target level as specified by NCEP guidelines. RESULTS: A total of 4888 patients from 5 regions of the United States were studied. Of these, 23% had fewer than 2 risk factors for coronary heart disease (CHD) and no evidence of CHD (low-risk group), 47% had 2 or more risk factors and no evidence of CHD (high-risk group), and 30% had established CHD. Overall, only 38% of patients achieved NCEP-specified LDL-C target levels; success rates were 68% among low-risk patients, 37% among high-risk patents, and 18% among patients with CHD. Drug therapy was significantly (P< or =.001) more effective than nondrug therapy in all patient risk groups. However, many patients treated with lipid-lowering drugs did not achieve LDL-C target levels. CONCLUSIONS: Large proportions of dyslipidemic patients receiving lipid-lowering therapy are not achieving NCEP LDL-C target levels. These findings indicate that more aggressive treatment of dyslipidemia is needed to attain goals established by NCEP guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Enzymatic Determination of Total Serum Cholesterol
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,125
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Furie, K. L., Kasner, S. E., Adams, R. J., Albers, G. W., Bush, R. L., Fagan, S. C., Halperin, J. L., Johnston, S. C., Katzan, I., Kernan, W. N., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181f7d043 · Cited by 1,492
Phillips, L. S., Branch, W. T., Cook, C. B., Doyle, J. P., El-Kebbi, I. M., Gallina, D. L., Miller, C. D., Ziemer, D. C., & Barnes, C. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-9-200111060-00012 · Cited by 1,370
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Overconfidence as a Cause of Diagnostic Error in Medicine
Berner, E. S., & Graber, M. L. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.001 · Cited by 1,034
Cooper, R., Cutler, J., Desvigne-Nickens, P., Fortmann, S. P., Friedman, L., Havlik, R., Hogelin, G., Marler, J., McGovern, P., Morosco, G., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3137 · Cited by 831
Self-citationKotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines
Mosca, L., Linfante, A. H., Benjamin, E. J., Berra, K., Hayes, S. N., Walsh, B. W., Fabunmi, R. P., Kwan, J., Mills, T., & Simpson, S. L. (2005) · Circulation · doi:10.1161/01.cir.0000154568.43333.82 · Cited by 757
Ballantyne, C. M., Houri, J., Notarbartolo, A., Melani, L., Lipka, L. J., Suresh, R., Sun, S., LeBeaut, A. P., Sager, P. T., & Veltri, E. P. (2003) · Circulation · doi:10.1161/01.cir.0000068312.21969.c8 · Cited by 687
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Circulation · doi:10.1161/circ.113.10.e409 · Cited by 541
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia
Civeira, F. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.11.010 · Cited by 495
Vale, M. J., Jelinek, M. V., Best, J. D., Dart, A. M., Grigg, L. E., Hare, D. L., Ho, B. P., Newman, R. W., & McNeil, J. J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.22.2775 · Cited by 381
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
Sachdeva, A., Cannon, C. P., Deedwania, P. C., LaBresh, K. A., Smith, S. C., Dai, D., Hernandez, A., & Fonarow, G. C. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.08.010 · Cited by 329
Goff, D. C., Bertoni, A. G., Kramer, H., Bonds, D., Blumenthal, R. S., Tsai, M. Y., & Psaty, B. M. (2006) · Circulation · doi:10.1161/circulationaha.105.552737 · Cited by 316
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Sex-Specific Trends in Midlife Coronary Heart Disease Risk and Prevalence
Towfighi, A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.318 · Cited by 308
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 306
Santschi, V. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.399 · Cited by 296
Tsuyuki, R. T. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1149 · Cited by 290
Ezetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
Urban, D., Pöss, J., Böhm, M., & Laufs, U. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.056 · Cited by 286
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270
Self-citationGet With the Guidelines for Cardiovascular Secondary Prevention: Pilot Results
LaBresh, K. A., Ellrodt, A. G., Gliklich, R., Liljestrand, J., & Peto, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.203 · Cited by 269
Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study
O’Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología · doi:10.1157/13116658 · Cited by 266
Cardiovascular Risk Factors. Insights From Framingham Heart Study
O'Donnell, C. J., & Elosua, R. (2008) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(08)60118-8 · Cited by 265
Hobbs, F. R. (2002) · Family Practice · doi:10.1093/fampra/19.6.596 · Cited by 253
Jones, M. L., Tomaro-Duchesneau, C., Martoni, C. J., & Prakash, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.758706 · Cited by 190
Parris, E. S., Lawrence, D. B., Mohn, L. A., & Long, L. B. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.595 · Cited by 155
Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy
Benner, J. S., Tierce, J. C., Ballantyne, C. M., Prasad, C., Bullano, M. F., Willey, V. J., Erbey, J., & Sugano, D. S. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422003-00003 · Cited by 115
Ziemer, D. C., Doyle, J. P., Barnes, C. S., Branch, W. T., Cook, C. B., El-Kebbi, I. M., Gallina, D. L., Kolm, P., Rhee, M. K., & Phillips, L. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.5.507 · Cited by 110
Hiratzka, L. F., Eagle, K. A., Liang, L., Fonarow, G. C., LaBresh, K. A., & Peterson, E. D. (2007) · Circulation · doi:10.1161/circulationaha.106.681247 · Cited by 75
Neutel, J. M., Bestermann, W. H., Dyess, E. M., Graff, A., Kursun, A., Sutradhar, S., & Yunis, C. (2009) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00058.x · Cited by 46
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Marquina, C., Zomer, E., Vargas-Torres, S., Zoungas, S., Ofori-Asenso, R., Liew, D., & Ademi, Z. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00936-0 · Cited by 34
Role of colesevelam in combination lipid-lowering therapy
Jones, M. R., & Nwose, O. M. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0037-0 · Cited by 27
Optimizing LDL-C Lowering With Statins
McKenney, J. M. (2004) · American Journal of Therapeutics · doi:10.1097/00045391-200401000-00011 · Cited by 27
Lowering LDL cholesterol in adults: a prospective, community-based practice initiative
Coodley, G. O., Jorgensen, M., Kirschenbaum, J., Sparks, C., Zeigler, L., & Albertson, B. D. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.02.031 · Cited by 23
Metadata
- Authors
- Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2000-02-28
- Volume
- 160
- Issue
- 4
- Pages
- 459
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2140072878
- Cited by
- 1,012
- References
- 21
- FWCI
- 87.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.